Ajooni Biotech Limited — Others, 14-08-2025: Statement of deviation(s) or variation(s) under Reg. 32

Ajooni Biotech has confirmed that there are no deviations in the utilization of proceeds from its Rights Issue. For the quarter ended June 30, 2025, the company has utilized the raised funds of approximately 42.31 crore as planned. This includes financing land acquisition, plant & machinery, working capital requirements, and general corporate purposes. This update assures shareholders that the capital raised is being deployed according to the original objectives, reflecting prudent financial management and transparency in fund usage.